EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study

Ferdinando D'Amico, Fernando Gomollón, Giorgos Bamias, Fernando Magro, Laura Targownik, Claudia Leitner iD, Tobias Heatta-Speicher, Naiara Michelena, Stefanie Kolterer, Jennifer Lapthorn, Laura Kauffman, Axel Dignass und 1 weitere

United European Gastroenterology Journal · 2024

DOI: 10.1002/ueg2.12572 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Ferdinando D'Amico und 12 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Biotherapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Crohn's disease and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) characterized by a progressive nature of the disease resulting in subsequent intestinal damage, limited efficacy of current treatments and suboptimal disease management and a significant burden for patients.

Objectives

The IBD‐PODCAST study aims to estimate the proportion of Crohn's disease and UC patients with suboptimal disease control (SDC) in a real‐world setting.

Methods

A non‐interventional and cross‐sectional study was conducted across 103 sites in 10 countries (Austria, Belgium, Canada, Germany, Greece, Italy, Portugal, Spain, Turkey, and UK). Criteria for SDC were based on STRIDE‐II criteria and adapted by an expert panel.

Results

2185 patients (Crohn's disease: n = 1,108, UC: n = 1077) with a mean (SD) age of 44.0 (14.8) years and mean (SD) disease duration of 12.4 (9.2) years were included (52.2% male). Ileal involvement was present in 39.1% of Crohn's disease patients, 35.3% of UC patients had extensive colitis. 77.3% of Crohn's disease and 65.3% of UC patients were on targeted immunomodulators and, according to STRIDE‐II‐based treatment phases, 85.6% of Crohn's disease and 85.4% of UC patients were assigned to the long‐term treatment phase. SDC was detected in 52.2% of Crohn's disease and 44.3% of UC patients predominantly due to impaired quality of life (QoL), clinically significant extraintestinal manifestations, steroid overuse, signs of active inflammation in UC and Crohn's disease, and active fistulas in Crohn's disease. More than one criterion was seen in 37% of patients with SDC. Opportunities for on‐label treatment optimization were observed in 49% of Crohn's disease and 61% of UC patients on advanced therapy.

Conclusion

The high percentage of SDC in this global, real‐world cohort suggests a large disease burden and high unmet medical need in IBD patients. Future analysis should focus on monitoring and responding to SDC in this cohort and on patients' QoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseColitis, UlcerativeHumansMaleFemaleCross-Sectional StudiesAdultMiddle AgedQuality of LifeEuropeSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

Crohn's diseaseSTRIDE II recommendationsextraintestinal manifestationsfistulainflammatory bowel diseasesquality of lifesteroidtreat to target strategyulcerative colitis

Autor:innen und Institutionen

  • Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Facultad de Medicina, IIS Aragón, Hospital Clínico Universitario "Lozano Blesa", CIBEREHD, Zaragoza, Spain.
  • GI-Unit, 3rd Academic Department of Internal Medicine, Sotiria Hospital, National & Kapodistrian University of Athens, Athens, Greece.
  • CINTESIS@RISE Departament, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Claudia Leitner

Förderung

  • AbbVie Biotherapeutics

Zitieren

APA

D'Amico, F., Gomollón, F., Bamias, G., Magro, F., Targownik, L., Leitner, C., Heatta-Speicher, T., Michelena, N., Kolterer, S., Lapthorn, J., Kauffman, L., Dignass, A., & IBD PODCAST investigators (2024). Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12572

Vancouver

D'Amico F, Gomollón F, Bamias G, Magro F, Targownik L, Leitner C, et al. Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12572

BibTeX
@article{DAmico2024,
  author = {D'Amico, Ferdinando and Gomollón, Fernando and Bamias, Giorgos and Magro, Fernando and Targownik, Laura and Leitner, Claudia and Heatta-Speicher, Tobias and Michelena, Naiara and Kolterer, Stefanie and Lapthorn, Jennifer and Kauffman, Laura and Dignass, Axel and IBD PODCAST investigators, IBD PODCAST investigators},
  title = {Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  doi = {10.1002/ueg2.12572}
}
Kostenlos starten →